Lower Serum n-3 Fatty Acid Level in Older Adults with Sarcopenia

The n-3 fatty acid (FA) has evoked considerable interest as a modifiable factor for maintenance of muscle health owing to its anti-inflammatory properties. To clarify this possibility, we investigated circulating n-3 FA level, a reliable biomarker of FA status in the body, in relation to sarcopenia...

Full description

Bibliographic Details
Main Authors: Il-Young Jang, Hee-Won Jung, Jin Hoon Park, Jeoung Hee Kim, Seungjoo Lee, Eunju Lee, Jin Young Lee, So Jeong Park, Da Ae Kim, Su Jung Kim, Hyun Ju Yoo, Beom-Jun Kim
Format: Article
Language:English
Published: MDPI AG 2020-09-01
Series:Nutrients
Subjects:
Online Access:https://www.mdpi.com/2072-6643/12/10/2959
Description
Summary:The n-3 fatty acid (FA) has evoked considerable interest as a modifiable factor for maintenance of muscle health owing to its anti-inflammatory properties. To clarify this possibility, we investigated circulating n-3 FA level, a reliable biomarker of FA status in the body, in relation to sarcopenia in a cohort of Asian older adults. Blood samples were collected from 125 participants who underwent comprehensive assessment of muscle mass and function. Serum FA level was measured by gas chromatography/mass spectrometry. Sarcopenia was diagnosed using the cut-off points specified for the Asian population. After adjusting for sex, age, and body mass index, subjects with sarcopenia and those with low muscle strength had 36.5% and 32.4% lower serum n-3 levels (<i>P</i> = 0.040 and 0.030), respectively, than controls. The odds ratios per standard deviation increment in serum n-3 level for sarcopenia and low muscle strength were 0.29 and 0.40 (<i>P</i> = 0.015 and 0.028), respectively. A higher serum n-3 level was significantly associated with greater muscle strength (<i>P</i> = 0.038). These findings suggest a possible protective effect of n-3 FA on human muscle homeostasis. Further well-designed large-scale longitudinal studies are necessary to understand the definite role of circulating n-3 FA level in sarcopenia risk assessment.
ISSN:2072-6643